IRIS
Mancuso, Maria Elisa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 663
SA - Sud America 448
NA - Nord America 350
EU - Europa 84
AF - Africa 26
Totale 1.571
Salva come PNG Salva come JPEG
Nazione #
BR - Brasile 364
US - Stati Uniti d'America 328
SG - Singapore 262
VN - Vietnam 220
CN - Cina 99
AR - Argentina 46
ID - Indonesia 37
EC - Ecuador 15
IT - Italia 14
BD - Bangladesh 13
DE - Germania 13
FI - Finlandia 12
MX - Messico 9
HK - Hong Kong 8
RU - Federazione Russa 8
AT - Austria 6
EG - Egitto 6
CA - Canada 5
CO - Colombia 5
FR - Francia 5
IE - Irlanda 5
NL - Olanda 5
VE - Venezuela 5
ZA - Sudafrica 5
GB - Regno Unito 4
IQ - Iraq 4
MA - Marocco 4
NG - Nigeria 4
PY - Paraguay 4
UA - Ucraina 4
AZ - Azerbaigian 3
CL - Cile 3
OM - Oman 3
PL - Polonia 3
TN - Tunisia 3
TR - Turchia 3
UY - Uruguay 3
BO - Bolivia 2
DO - Repubblica Dominicana 2
HN - Honduras 2
IL - Israele 2
JP - Giappone 2
PK - Pakistan 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
CI - Costa d'Avorio 1
DZ - Algeria 1
GT - Guatemala 1
IN - India 1
JM - Giamaica 1
KE - Kenya 1
LT - Lituania 1
NP - Nepal 1
PE - Perù 1
PS - Palestinian Territory 1
SE - Svezia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
UZ - Uzbekistan 1
Totale 1.571
Salva come PNG Salva come JPEG
Città #
Ho Chi Minh City 90
Dallas 84
Beijing 79
Ashburn 49
Hanoi 38
Singapore 37
Wilmington 33
The Dalles 22
São Paulo 19
Chandler 15
Thái Bình 13
Curitiba 12
Helsinki 12
San Mateo 12
Haiphong 11
Ann Arbor 10
Rio de Janeiro 10
Da Nang 9
Jakarta 9
Hong Kong 8
Hải Dương 8
New York 8
Thái Nguyên 8
Brasília 7
Buenos Aires 7
Leawood 7
Porto Alegre 7
Shanghai 7
Assago 6
Can Tho 6
Guayaquil 6
Los Angeles 6
Boardman 5
Dublin 5
Lawrence 5
Princeton 5
Ribeirão Preto 5
Uberlândia 5
Woodbridge 5
Belo Horizonte 4
Benin City 4
Biên Hòa 4
Cairo 4
Campinas 4
Contagem 4
Duque de Caxias 4
Ha Long 4
Manaus 4
Milan 4
Posadas 4
Vila Velha 4
Amsterdam 3
Anápolis 3
Bandung 3
Caxias do Sul 3
Dhaka 3
Fortaleza 3
Guarulhos 3
Itaquaquecetuba 3
Johannesburg 3
Lấp Vò 3
Maceió 3
Mexico City 3
Nova Iguaçu 3
Paris 3
Passo Fundo 3
Praia Grande 3
Quito 3
Santo André 3
Toronto 3
Warsaw 3
Al Mansurah 2
Asunción 2
Atlanta 2
Baghdad 2
Baku 2
Boston 2
Burzaco 2
Cabo Frio 2
Cachoeira do Sul 2
Cachoeiras de Macacu 2
Campo Grande 2
Campos dos Goytacazes 2
Canoas 2
Caracas 2
Carapicuíba 2
Criciúma 2
Ezeiza 2
Fairfield 2
Florianópolis 2
Franca 2
Guaíba 2
Ibiúna 2
Istanbul 2
Itabaiana 2
Juazeiro do Norte 2
Limeira 2
Marrakesh 2
Montreal 2
Ninh Bình 2
Totale 856
Salva come PNG Salva come JPEG
Nome #
Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response 68
High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study 54
Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy 50
Uniportal and three-portal video-assisted thoracic surgery lobectomy: analysis of the Italian video-assisted thoracic surgery group database 44
Mortality and causes of death in Italian persons with haemophilia, 1990-2007 42
What counts more: the patient, the surgical technique, or the hospital? A multivariable analysis of factors affecting perioperative complications of pulmonary lobectomy by video-assisted thoracoscopic surgery from a large nationwide registry 41
Compromised Lung Volume and Hemostatic Abnormalities in COVID-19 Pneumonia: Results from an Observational Study on 510 Consecutive Patients 33
Predicting a Prolonged Air Leak After Video-Assisted Thoracic Surgery, Is It Really Possible? 26
Ageing successfully with haemophilia : A multidisciplinary programme 24
A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors 24
Evaluation of an automated chromogenic assay for Factor VIII clotting activity measurement in patients affected by haemophilia A 24
Peri-operative and post-operative management of haemophiliac patients without inhibitors 23
Comparison of thrombin generation for paired-platelet-rich plasma collected with and without corn trypsin inhibitor from hemophiliacs treated with factor-VIII inhibitor bypassing agents 23
Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry 23
Arteriovenous fistula as stable venous access in children with severe haemophilia 23
Severe hemophilia with mild bleeding phenotype : molecular characterization and global coagulation profile 23
Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study 22
A recurrent F8 mutation (c.6046C>T) causing hemophilia A in 8% of northern Italian patients : evidence for a founder effect 22
Association study between XRCC1 gene polymorphisms and sporadic amyotrophic lateral sclerosis 21
Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry 21
Deep intronic variations may cause mild hemophilia A 21
Involvement of the IgE-basophil system and mild complement activation in haemophilia B with anti-factor IX neutralizing antibodies and anaphylaxis 21
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A 20
F8 mRNA studies in haemophilia A patients with different splice site mutations 20
Fatigue and exercise intolerance in mitochondrial diseases. Literature revision and experience of the Italian Network of mitochondrial diseases 20
Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders 20
Synoviorthesis in haemophilia patients with inhibitors 20
Dental surgery in inherited bleeding disorders with minimal factor support: commentary 20
Results from a large multinational clinical trial (guardian (TM) 1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy 20
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study 20
Cost-utility analysis of prophylaxis versus treatment on demand in severe hemophilia A 20
A catastrophic case of skin gangrene 19
Cognitive and psychological profiles in treatment compliance: a study in an elderly population with hemophilia 19
Congenital afibrinogenemia 19
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study 19
Prevention of arthropathy in haemophilia: prophylaxis 19
Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A : a patient-level meta-analysis 18
Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors 18
Platelets from glioblastoma patients promote angiogenesis of tumor endothelial cells and exhibit increased VEGF content and release 18
Circulating endothelial cells (CECs) and progenitors (CEPs) in severe haemophiliacs with different clinical phenotype 18
Increased VEGF levels in a case of papillary tumor of the pineal region with intracranial hemorrhage: A potential surrogate indicator of tumor angiogenesis and aggressiveness? 18
Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A 18
Barriers to primary prophylaxis in haemophilic children: the issue of the venous access 18
Applying a deliberation model to the analysis of consultations in haemophilia: Implications for doctor-patient communication 18
Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters 18
Venous access in haemophilic children: choice and management 17
Global Emerging HEmophilia Panel (GEHEP): a multinational collaboration for Advancing hemophilia research and treatment 17
Factor VIII products and inhibitor development in severe hemophilia A 17
Implicazioni economiche del trattamento dei pazienti emofilici con inibitori: una revisione sistematica della letteratura 17
Factors influencing the long-term outcome of primary total knee replacement in haemophiliacs : a review of 116 procedures at a single institution 17
Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients 17
Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study 16
Orthopaedic management of haemophilia arthropathy of the ankle 16
Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) 16
Handwriting Analysis in Children and Adolescents with Hemophilia : A Pilot Study 16
Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management 16
Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors 16
Peri-operative and post-operative management of haemophiliac patients with inhibitors 15
Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII: Considerations on the differentiation between the 2 circulating anticoagulants 15
High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C 15
Whole-exome sequencing to identify genetic risk variants underlying inhibitor development in severe hemophilia A patients 15
The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort 15
Integrated postural analysis in children with haemophilia 14
Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice 14
Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors 14
Polypharmacy in older adults with severe haemophilia 14
Improved treatment feasibility in children with hemophilia using arteriovenous fistulae: the results after seven years of follow-up 14
The natural history of hepatitis C virus infection in Italian patients with von Willebrand's disease: a cohort study 14
Investigational drugs for coagulation disorders 14
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) 14
Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: dosing, pharmacokinetics and clinical efficacy 13
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial 13
Rescue FVIII replacement to secure haemostasis in a patient with haemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement 13
Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease 13
Radiosynoviorthesis in children with haemophilia 12
X Chromosome inactivation: a modifier of factor VIII and IX plasma levels and bleeding phenotype in Haemophilia carriers 12
Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A 11
Haemophilia care in children - benefits of early prophylaxis for inhibitor prevention 11
F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort 11
The thrombin generation assay distinguishes inhibitor from non‐inhibitor patients with severe haemophilia A 7
Muscle function deterioration in patients with haemophilia: Prospective experience from Costa Rica 6
Befovacimab, an anti‐tissue factor pathway inhibitor antibody: Early termination of the multiple‐dose, dose‐escalating Phase 2 study due to thrombosis 5
The predictive value of factor VIII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH 5
Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors 5
Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication 4
Low thrombin generation during major orthopaedic surgery fails to predict the bleeding risk in inhibitor patients treated with bypassing agents 4
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors 4
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors 4
The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing 4
Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis 3
Health‐related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study 3
PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A 3
Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B 3
Synovitis and joint health in patients with haemophilia: Statements from a European e‐Delphi consensus study 3
High adherence to prophylaxis regimens in haemophilia B patients receiving rIX‐FP: Evidence from clinical trials and real‐world practice 2
Extended half-life factor IX prophylaxis up to every 21 days in hemophilia B: a longitudinal analysis of the efficacy and safety in selected adult patients 2
Totale 1.671
Salva come PNG Salva come JPEG
Categoria #
all - tutte 7.501
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.501
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202161 0 0 0 0 0 19 11 5 14 5 1 6
2021/202228 1 0 0 7 0 0 2 6 1 3 7 1
2022/202350 12 1 5 4 2 4 0 5 11 6 0 0
2023/202445 2 7 8 1 1 6 0 0 2 0 9 9
2024/202580 8 0 1 2 1 7 4 5 10 30 5 7
2025/20261.401 211 121 278 571 194 26 0 0 0 0 0 0
Totale 1.671